updated 4/28/2011 4:17:44 PM ET 2011-04-28T20:17:44

SALT LAKE CITY, April 28, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on developing and commercializing novel treatments for cancer, today announced it will hold a conference call on Tuesday, May 10, 2011 at 4:30 p.m. ET (1:30 p.m. PT) to discuss financial results for its fiscal third quarter 2011 ended March 31, 2011.

The conference call will be hosted by Adrian Hobden, Ph.D., President and Chief Executive Officer and Robert Lollini, Chief Financial Officer and Treasurer.

To participate, please dial 877-312-5447 (USA) or 253-237-1129 (International); Conference ID: 63522540. To access the live web cast please visit the Investor Relations section on the corporate web site at www.myrexis.com .

A replay of the conference call will be available beginning May 10, 2011 at 7:30 p.m. ET (4:30 p.m. PT) and ending on June 10, 2011 by dialing 800-642-1687 (USA) or 706-645-9291 (International), Conference ID: 63522540. A replay of the webcast will also be available on the corporate website for one month, through June 10, 2011.

About Myrexis, Inc.

Myrexis, Inc. is a biotechnology company focused on developing and commercializing novel treatments for cancer. The Company has leveraged a unique understanding of the genetic causes of human disease to generate a strong pipeline of clinical and preclinical product candidates. These include compounds with distinct mechanisms of action and novel chemical structures that have first-in-class and/or best-in-class therapeutic potential. Myrexis is led by an experienced management team with expertise in all aspects of pre-clinical, clinical and commercial drug development.

The Company's oncology pipeline is led by Azixa (verubulin, MPC-6827), a novel small molecule microtubule destabilizing agent in Phase 2b clinical development for the treatment of brain cancers. Additional novel, potent, small molecule oncology compounds include MPC-3100, a fully-synthetic inhibitor of Hsp90 in Phase 1; and MPC-9528, a Cancer Metabolism Inhibitor (CMI) in IND-enabling studies. Myrexis is also evaluating MPI-0485520, an orally bioavailable, potent and selective small molecule inhibitor of type I interferon production that is being developed for the treatment of autoimmune diseases.

For more information, please visit www.myrexis.com .

The Myrexis, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6327

Azixa, Myrexis and the Myrexis logo are trademarks or registered trademarks of Myrexis, Inc. in the United States and foreign countries.

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the attributes, expected development, and potential efficacy of Myrexis' product candidates, including Azixa (MPC-6827). These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to, the factors discussed under the heading "Risk Factors" contained in Myrexis' Form 10-K, for the year ended June 30, 2010, which was filed with the Securities and Exchange Commission on September 13, 2010, as well as any updates to those risk factors filed from time to time in Myrexis' Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myrexis undertakes no duty to update this information unless required by law.

CONTACT: Myrexis, Inc.
         Wayne Laslie,
         Chief Operating Officer
         (corporate)
         801-214-7822
         investor.relations@myrexis.com
         
         The Ruth Group
         Stephanie Carrington (investors)
         (646) 536-7017
         scarrington@theruthgroup.com
         
         Jason Rando (media)
         (646) 536-7025
         jrando@theruthgroup.com

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved

Discuss:

Discussion comments

,

Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 2.78%
$30K home equity loan FICO 5.78%
$75K home equity loan FICO 4.54%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.57%
13.57%
Cash Back Cards 17.91%
17.91%
Rewards Cards 17.15%
17.15%
Source: Bankrate.com